Evoke's sole treatment fails to evoke the FDA's confidence, as agency rejects Gimoti after flagging concerns last month
Having outlined a list of lingering concerns with Evoke Pharma’s marketing application for its sole drug last month, the FDA solidified its dissent with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
